Monitor whether Bleichroeder continues to accumulate shares or eventually converts to a 13D filing, which would signal a shift from passive to active intent. The incremental increase is routine for a passive holder.
CUE drugs
CUE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $18.66entry
- T+1 · 5d ago −6.22%α −5.86% · $17.50
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Bleichroeder LP filed an amended Schedule 13G disclosing beneficial ownership of 663,009 shares (8.77%) of Cue Biopharma as of September 30, 2026, up from 8.50% in the prior filing. The increase reflects a combination of share purchases and warrant exercises, but the filing maintains passive intent.
Key Financial Metrics
Key Facts
- Bleichroeder LP reported beneficial ownership of 663,009 shares of Cue Biopharma common stock, representing 8.77% of shares outstanding as of September 30, 2026.
- The stake includes 366,152 shares of common stock and 296,857 shares issuable upon exercise of warrants.
- This is an increase from the prior filing (October 8, 2026) which disclosed 644,916 shares (8.50%).
- The filing is made under Rule 13d-1(b), confirming passive investment intent.
- Bleichroeder LP is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940.
Financial Impact
Bleichroeder's stake increased by approximately 18,093 shares (from 644,916 to 663,009), representing a 0.27 percentage point increase in ownership. At the current market cap of $136M, the stake is valued at approximately $11.9M.
Risk Factors
- No material risks identified from this routine passive stake amendment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001420506-26-002561 |
| Document: 0001420506-26-002561-index-headers.html | 0001420506-26-002561 |
| Document: 0001420506-26-002561-index.html | 0001420506-26-002561 |
| Document: 0001420506-26-002561.txt | 0001420506-26-002561 |
Track record
30 reports on CUE
9 of 13 bullish or bearish reports moved the stock their way by T+1. Best: +519.50% at T+20 after the Apr 7, 2026 report. 11 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bearish 4/10 Entry $13.83 Now $14.10 −1.95% settles Nov 18
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $15.81 Now $14.10 −10.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $14.96 Now $14.10 +5.75% settles Nov 17
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $16.39 Now $14.10 −13.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Viewing Entry $18.66 to $17.50 Now $14.10 −24.44% ▼ −6.22% −5.86% vs SPY
- Oct 14, 20264w ago Insider Cluster Bearish 4/10 Entry $18.67 to $16.71 Now $14.10 +24.48% ▲ +10.50% +9.39% vs SPY
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $18.60 to $18.67 Now $14.10 −24.19% ▲ +0.38% +0.09% vs SPY
- Oct 8, 20265w ago SC 13G/A Neutral 4/10 Entry $22.33 to $27.66 Now $14.10 −36.86% ▲ +23.87% +23.27% vs SPY
- Sep 21, 20268w ago 8-K Bullish 7/10 Entry $28.27 to $30.90 Now $14.10 −50.12% ▲ +9.30% +9.32% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $28.27 to $30.90 Now $14.10 −50.12% ▲ +9.30% +9.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers